Cassava Sciences (NASDAQ:FLNA – Get Free Report) and Madrigal Pharmaceuticals (NASDAQ:MDGL – Get Free Report) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, dividends and earnings.
Profitability
This table compares Cassava Sciences and Madrigal Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Cassava Sciences | N/A | -53.90% | -34.20% |
| Madrigal Pharmaceuticals | -27.32% | -50.15% | -25.44% |
Earnings & Valuation
This table compares Cassava Sciences and Madrigal Pharmaceuticals”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Cassava Sciences | N/A | N/A | -$90.97 million | ($1.61) | -0.84 |
| Madrigal Pharmaceuticals | $958.40 million | 11.75 | -$288.28 million | ($12.80) | -38.14 |
Cassava Sciences has higher earnings, but lower revenue than Madrigal Pharmaceuticals. Madrigal Pharmaceuticals is trading at a lower price-to-earnings ratio than Cassava Sciences, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
Cassava Sciences has a beta of -0.71, suggesting that its stock price is 171% less volatile than the S&P 500. Comparatively, Madrigal Pharmaceuticals has a beta of -1.07, suggesting that its stock price is 207% less volatile than the S&P 500.
Analyst Ratings
This is a breakdown of recent ratings and recommmendations for Cassava Sciences and Madrigal Pharmaceuticals, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Cassava Sciences | 1 | 0 | 1 | 0 | 2.00 |
| Madrigal Pharmaceuticals | 1 | 3 | 13 | 1 | 2.78 |
Cassava Sciences presently has a consensus target price of $5.00, suggesting a potential upside of 267.65%. Madrigal Pharmaceuticals has a consensus target price of $687.00, suggesting a potential upside of 40.74%. Given Cassava Sciences’ higher possible upside, research analysts clearly believe Cassava Sciences is more favorable than Madrigal Pharmaceuticals.
Institutional and Insider Ownership
38.1% of Cassava Sciences shares are owned by institutional investors. Comparatively, 98.5% of Madrigal Pharmaceuticals shares are owned by institutional investors. 4.6% of Cassava Sciences shares are owned by company insiders. Comparatively, 17.6% of Madrigal Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Summary
Madrigal Pharmaceuticals beats Cassava Sciences on 8 of the 14 factors compared between the two stocks.
About Cassava Sciences
Filana Therapeutics Inc is a biotechnology company focused on developing novel, investigational therapies to modulate the filamin A protein for the treatment of central nervous system disorders, such as tuberous sclerosis complex (TSC)-related epilepsy, and other diseases associated with dysregulation or overexpression of filamin A. Its therapeutic product candidate, simufilam, is a proprietary small molecule oral treatment drug being studied for the treatment of TSC-related epilepsy.
About Madrigal Pharmaceuticals
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.
Receive News & Ratings for Cassava Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cassava Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
